Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke

Blood

Volumn 111, Issue 3, 2008, Pages 1282-1286

  Pruissen, D Martijn O ^a   Slooter, Arjen J C ^b   Rosendaal, Frits R ^c   Van Der Graaf, Yolanda ^b   Algra, Ale ^a,b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; ORAL CONTRACEPTIVE AGENT; PHENYLALANINE; PROTEIN SUBUNIT; TYROSINE;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE FUNCTION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 38949209525     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-110254     Document Type: Article

References (32)

1. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-78.
2. MacClellan LR, Mitchell BD, Cole JW, et al. Familial aggregation of ischemic stroke in young women: the Stroke Prevention in Young Women Study. Genet Epidemiol. 2006;30:602-608.
3. Pezzini A, Grassi M, Iacoviello L, et al. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry. 2007;78:271-276.
4. Aznar J, Mira Y, Vaya A, et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91:1031-1034.
5. Slooter AJ, Rosendaal FR, Tanis BC, et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213-1217.
6. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006;91:844-847.
7. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558-1566.
8. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361:1424-1431.
9. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112:223-228.
10. Dunn EJ, Ariens RA, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood. 2004;103:1735-1740.
11. Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96:988-995.
12. Shafey M, Anderson JL, Scarvelis D, et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 2007;97:635-641.
13. Elbaz A, Poirier O, Canaple S, et al. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood. 2000;95:586-591.
14. Gallivan L, Markham AF, Anwar R. The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost. 1999;82:1368-1370.
15. Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 1999;93:897-905.
16. Reiner AP, Frank MB, Schwartz SM, et al. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol. 2002;116:376-382.
17. Komanasin N, Catto AJ, Futers TS, et al. A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost. 2005;3:2487-2496.
18. Reiner AP, Heckbert SR, Vos HL, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood. 2003;102:25-30.
19. Fruzzetti F. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol. 1999;180:S369-S374.
20. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202-1208.
21. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14:143-149.
22. National Center for Biotechnology Information. Single nucleotide polymorphism database. Available at: http://www.ncbi.nlm.nih.gov/projects/SNP. Accessed July 6, 2007.
23. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
24. Sarti C, Stegmayr B, Tolonen H, et al. Are changes in mortality from stroke caused by changes in stroke event rates or case fatality? Results from the WHO MONICA Project. Stroke. 2003;34:1833-1840.
25. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas. 2004;48:39-49.
26. Hunter DJ, Manson JE, Colditz GA, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception. 1997;56:373-378.
27. Ariyaratnam R, Casas YP, Whittaker Y, et al. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLOS Med. 2007;4:e131.
28. Petitti DB. Clinical practice: combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443-1450.
29. Bots ML, Berger-van Sijl M, Jager-Geurts MH, et al. Incidence of cerebrovascular disease in The Netherlands in 2000. In: Jager-Geurts MH, Peters RJG, van Dis SJ, Bots ML, eds. Cardiovascular disease in The Netherlands 2006. The Hague: Netherlands Heart Foundation; 2006:35-56.
30. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95:370-374.
31. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44:62-72.
32. World Health Organization. World Health Report 2005: Make Every Mother and Child Count. Geneva: World Health Organization; 2005.